San Diego-primarily based Viking Therapeutics marked itself as a significant competitor while in the weight loss drug market in February after revealing promising data from the mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection As well as in March t